Copyright
©The Author(s) 2023.
World J Virol. Jun 25, 2023; 12(3): 193-203
Published online Jun 25, 2023. doi: 10.5501/wjv.v12.i3.193
Published online Jun 25, 2023. doi: 10.5501/wjv.v12.i3.193
Criteria | RCPCH[71] | WHO[72] | CDC[73] |
Age | ND | < 21 | < 19 |
Clinical | Persistent fever > 38.5 °C. Evidence of single or multi-organ dysfunction with additional features1 | Fever ≥ 3 d; two of the following: (1) Mucocutaneous inflammation signs; (2) Hypotension or shock; (3) Cardiac issues2; (4) Evidence of coagulopathy; and (5) Acute gastrointestinal problems | Fever ≥ 38.0 °C for ≥ 24 h; multisystemic disease involving multiple (≥ 2) organs (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological). Requirement of hospitalization |
Inflammatory markers | Neutrophilia, elevated CRP and lymphopenia | Elevated markers (such as ESR, CRP or procalcitonin) | Elevated CRP, ESR, fibrinogen, procalcitonin, d-dimer, ferritin, neutrophils, LDH, or IL-6 or reduced albumin and/or lymphocytes |
COVID-19 test | Positive or negative SARS-CoV-2 RT-PCR test | Evidence of COVID-19 (via RT-PCR, antigen test, or serology) or probable contact with patients contaminated with SARS-CoV-2 | RT-PCR, serology or antigen test positive for COVID-19 (currently or in recent period) or exposure to the virus within 4 wk prior to symptom onset |
Exclusion factors | Exclusion of any other microbial cause | No other obvious etiology for the inflammation | Absence of other plausible alternative diagnoses |
- Citation: Silva Luz M, Lemos FFB, Rocha Pinheiro SL, Marques HS, de Oliveira Silva LG, Calmon MS, da Costa Evangelista K, Freire de Melo F. Pediatric multisystem inflammatory syndrome associated with COVID-19: Insights in pathogenesis and clinical management. World J Virol 2023; 12(3): 193-203
- URL: https://www.wjgnet.com/2220-3249/full/v12/i3/193.htm
- DOI: https://dx.doi.org/10.5501/wjv.v12.i3.193